Voyager Therapeutics. has filed a patent for compositions and methods using viral vectors to deliver antibodies or antibody fragments targeting tau proteins for disease prevention and treatment. The patent includes specific nucleotide sequences for encoding the antibodies. GlobalData’s report on Voyager Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Voyager Therapeutics, Adeno-associated virus vectors was a key innovation area identified from patents. Voyager Therapeutics's grant share as of January 2024 was 13%. Grant share is based on the ratio of number of grants to total number of patents.
Patent filed for viral vectors encoding antibodies for disease treatment
A patent application (Publication Number: US20240000971A1) has been filed for an isolated nucleic acid containing a transgene that encodes an antibody or antibody fragment targeting tau. The nucleic acid includes specific sequences for the heavy chain variable region (VH) and light chain variable region (VL), with options for sequence identity percentages. Additionally, the nucleic acid may contain a signal sequence located relative to the VH and/or VL sequences, with various options for the signal sequence's identity.
Furthermore, the patent application includes claims related to the arrangement of the VH and VL sequences, the presence of a linker between them, and the inclusion of specific sequences for the linker. The application also covers the use of the nucleic acid to produce isolated antibodies or antibody fragments, as well as the incorporation of the transgene into a viral genome, specifically an adeno-associated viral genome, for therapeutic purposes in treating tauopathies such as Alzheimer's disease and other related conditions. The patent application also details the composition of AAV viral particles, vectors, host cells, and pharmaceutical compositions containing the nucleic acid, along with methods for producing AAV particles and treating tauopathies in subjects using the disclosed compositions.
To know more about GlobalData’s detailed insights on Voyager Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
